Premium
Moxonidine, a Mixed a 2 ‐Adrenergic and Imidazoline Receptor Agonist, Identifies a Novel Adrenergic Target for Spinal Analgesia
Author(s) -
STONE LAURA S.,
FAIRBANKS CAROLYN A.,
WILCOX GEORGE L.
Publication year - 2003
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1304.051
Subject(s) - moxonidine , imidazoline receptor , clonidine , agonist , analgesic , alpha 2 adrenergic receptor , neuropathic pain , adrenergic , pharmacology , alpha (finance) , chemistry , adrenergic receptor , adrenergic agonist , medicine , receptor , anesthesia , surgery , construct validity , patient satisfaction
A bstract : Moxonidine is a mixed a 2 ‐adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. Intrathecal (i.t.) moxonidine has been found to possess analgesic activity that, in contrast to the majority of a 2 ‐adrenoceptor (a 2 AR) agonists, does not require activation of the a 2A AR subtype, which mediates many of the side effects associated with a 2 AR use. In addition, moxonidine (i.t.) interacts in a synergistic manner with opioid agonists and this synergy is retained in neuropathic pain states. Moxonidine may therefore be clinically useful in the treatment of chronic neuropathic pain, either alone or as a coadjuvant with opioids.